Angelini Ventures invierte en una tecnología estadounidense contra la epilepsia

Roma - 29 de mayo de 2023 - Angelini Ventures, la sociedad internacional de capital riesgo de Angelini Industries, ha invertido 6 millones de dólares en Cadence Neuroscience, una start-up estadounidense que está desarrollando, en colaboración con investigadores de la Clínica Mayo una nueva terapia de neuromodulación para el tratamiento de la epilepsia focal resistente a fármacos en niños y adultos, basada en un software capaz de captar las señales asociadas a la epilepsia en el trazado del electroencefalograma y contrarrestarlas con una estimulación eléctrica puntual destinada a eliminar o reducir las crisis.

Los 6 millones de dólares invertidos por Angelini Ventures forman parte de la financiación global de 26 millones de dólares, que representa la "ronda Serie B", la segunda fase de crecimiento de Cadence Neuroscience, destinada a completar los ensayos clínicos y obtener la aprobación de la Food and Drug Administration (FDA). La ronda está liderada por Angelini Lumira Bioscience Fund (el fondo norteamericano creado por Lumira Ventures y Angelini Ventures), y ha contado con la participación de F-Prime Capital, LivaNova PLC, Angelini Ventures, Spectrum Financial Services y la Clínica Mayo, además de JAZZ Venture Partners.

"Inversiones como ésta, que realizamos con Angelini Ventures", comenta Sergio Marullo di Condojanni, consejero delegado de Angelini Industries, "responden plenamente a nuestra estrategia de crecimiento en el área terapéutica de los trastornos neurológicos y están en perfecta sintonía con la visión a largo plazo que un grupo empresarial como el nuestro lleva en su ADN. Además de ser una oportunidad potencial en términos de desarrollo, esta participación también responde plenamente a nuestra misión, que es, ante todo, cuidar de los pacientes y de su calidad de vida".

"La tecnología desarrollada por Cadence Neuroscience tiene el potencial de convertirse en un punto de referencia para el tratamiento de la epilepsia resistente a fármacos y otras enfermedades que afectan al cerebro", destaca Paolo Di Giorgio, CEO de Angelini Ventures. "Esta inversión se enmarca en nuestra estrategia de centrarnos a nivel internacional en empresas innovadoras y de alta tecnología en los sectores de las ciencias de la vida, la salud digital y la biotecnología, con el fin de identificar, financiar e implementar soluciones que innoven los modelos sanitarios tradicionales".

Con inversiones previstas por valor de 300 millones de euros en Europa, Norteamérica e Israel, Angelini Ventures contribuye la estrategia de crecimiento de Angelini Industries, un grupo industrial multinacional con 5.800 empleados y unos ingresos de 2.000 millones de euros en los sectores de la salud, los bienes de consumo, la tecnología industrial y los servicios financieros.

Acerca de Angelini Industries

Angelini Industries es un grupo industrial multinacional fundado en Ancona en 1919 por Francesco Angelini. Actualmente, representa una realidad industrial sólida y articulada que emplea a unas 5.800 personas y opera en 21 países del mundo, con unos ingresos superiores a los 2.000 millones de euros, generados en los sectores de la salud, la tecnología industrial y los bienes de consumo. Angelini Industries opera en el sector farmacéutico con Angelini Pharma, que investiga, desarrolla y comercializa soluciones sanitarias centradas, principalmente, en aspectos de salud del cerebro, incluyendo salud mental y epilepsia y atención sanitaria del consumidor.

Rome –25 May 2023 – Angelini Ventures, the international venture capital company of Angelini Industries, has invested US$6 million in Cadence Neuroscience, a US startup that is developing, in collaboration with Mayo Clinic researchers, a new neuromodulation therapy for the treatment of focal drug-resistant epilepsy in paediatric and adult patients. The treatment is based on software capable of detecting epilepsy-related signals recorded in the electroencephalogram (EEG) and countering them with targeted electrical stimulation to eliminate or reduce seizures.

The US$6 million investment by Angelini Ventures is part of new total funding of US$26 million, representing the Series B round, i.e., the second growth stage for Cadence Neuroscience, which aims to complete the preliminary clinical studies and obtain approval from the Food and Drug Administration (FDA). The round was led by Angelini Lumira Bioscience Fund (the North American fund created by Lumira Ventures and Angelini Ventures) and involved other new investors: F-Prime Capital, LivaNova PLC, Angelini Ventures, Spectrum Financial Services, and Mayo Clinic, along with JAZZ Venture Partners, which led the initial Series A round. Gerry Brunk from Lumira Ventures and Kevin Chu from F-Prime Capital will join the Board of Directors of Cadence Neuroscience.

"Investments like this, which we are making with Angelini Ventures," says Sergio Marullo di Condojanni, CEO of Angelini Industries, "fully align with our growth strategy in the neurological disorders area and are in perfect harmony with the long-term vision that is written into the DNA of an entrepreneurial group like ours. In addition to being a potential development opportunity, this investment fully meets our mission, which is primarily to take care of patients and improve their quality of life."

"The technology developed by Cadence Neuroscience has the potential to become a benchmark for the treatment of drug-resistant epilepsy and other brain-related conditions," notes Paolo Di Giorgio, CEO of Angelini Ventures. "This investment is part of our strategy to focus internationally on innovative and highly technological players in the life sciences, digital health, and biotechnology sectors. Our goal is to identify, finance, and implement solutions that innovate traditional healthcare models."

With investments totalling €300 million, €70 million of which is already planned, in Europe, North America, and Israel, with a particular focus on brain health and market segments targeting women, children, and elderly people, Angelini Ventures is aligned with the growth and innovation strategy of Angelini Industries, a multinational industrial group with 5,800 employees and €2 billion in revenues in the healthcare, consumer goods, and industrial technology sectors.

Cadence Neuroscience is a startup based in Redmond, near Seattle, founded in 2017. It has developed a new technology for the treatment of focal drug-resistant epilepsy in paediatric and adult patients based on research conducted by the neurology and neurosurgery team at Mayo Clinic, led by neurologist and epilepsy specialist Gregory Worrell.

Cadence Neuroscience has developed software capable of identifying precise epilepsy-related signals recorded in the EEG and modulating them through precise electrical impulses with the aim of eliminating or reducing seizures. The software is installed in a small permanent neural implant that generates continuous cortical electrical stimulation modulated on the basis of the brain impulses monitored by the software itself. In this way, the system developed by Cadence Neuroscience aims to offer targeted and personalised therapy.

Media contacts:

Angelini Industries

Alessandra Favilli – Group Chief Communication Officer

alessandra.favilli@angeliniholding.com – press@angeliniindustries.com

SEC Newgate Italia

Daniele Pinosa – daniele.pinosa@secnewgate.it – tel. +39 3357233872

Fausta Tagliarini – fausta.tagliarini@secnewgate.it – tel. +39 3476474513

Daniele Murgia – daniele.murgia@secnewgate.it – tel. +39 3384330031